This HTML5 document contains 64 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n22http://linked.opendata.cz/resource/drugbank/drug/DB00114/identifier/chebi/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n12http://linked.opendata.cz/resource/drugbank/company/
n26http://linked.opendata.cz/resource/mesh/concept/
foafhttp://xmlns.com/foaf/0.1/
n6http://linked.opendata.cz/resource/drugbank/drug/DB00114/identifier/wikipedia/
n5http://linked.opendata.cz/resource/drugbank/drug/DB00114/identifier/pharmgkb/
n21http://linked.opendata.cz/resource/drugbank/drug/DB00114/identifier/kegg-compound/
n18http://linked.opendata.cz/resource/drugbank/drug/DB00114/identifier/pdb/
n15http://linked.opendata.cz/resource/drugbank/drug/DB00114/identifier/pubchem-compound/
n19http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n17http://linked.opendata.cz/resource/drugbank/drug/DB00114/identifier/kegg-drug/
n16http://linked.opendata.cz/resource/drugbank/drug/DB00114/identifier/pubchem-substance/
n20http://linked.opendata.cz/resource/drugbank/drug/DB00114/identifier/drugbank/
n8http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n11http://www.pdrhealth.com/drug_info/nmdrugprofiles/nutsupdrugs/
n25http://linked.opendata.cz/ontology/mesh/
n3http://linked.opendata.cz/ontology/drugbank/
n9http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n23http://linked.opendata.cz/resource/drugbank/drug/DB00114/identifier/chemspider/
n14http://linked.opendata.cz/resource/atc/
n13http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00114
rdf:type
n3:Drug
n3:description
This is the active form of vitamin B6 serving as a coenzyme for synthesis of amino acids, neurotransmitters (serotonin, norepinephrine), sphingolipids, aminolevulinic acid. During transamination of amino acids, pyridoxal phosphate is transiently converted into pyridoxamine phosphate (pyridoxamine). [PubChem]
n3:group
nutraceutical
n3:indication
For nutritional supplementation and for treating dietary shortage or imbalance.
owl:sameAs
n8:DB00114 n19:DB00114
dcterms:title
Pyridoxal Phosphate
adms:identifier
n5:PA164749650 n6:Pyridoxal-phosphate n15:1051 n16:46506428 n17:D00006 n18:PLP n20:DB00114 n21:C00018 n22:18405 n23:1022
n3:mechanismOfAction
Pyridoxal Phosphate is a coenzyme of many enzymatic reactions. It is the active form of vitamin B6 which comprises three natural organic compounds, pyridoxal, pyridoxamine and pyridoxine. Pyridoxal phosphate acts as a coenzyme in all transamination reactions, and in some decarboxylation and deamination reactions of amino acids. The aldehyde group of pyridoxal phosphate forms a Schiff-base linkage with the epsilon-amino group of a specific lysine group of the aminotransferase enzyme. The alpha-amino group of the amino acid substrate displaces the epsilon-amino group of the active-site lysine residue. The resulting aldimine becomes deprotonated to become a quinoid intermediate, which in turn accepts a proton at a different position to become a ketimine. The resulting ketimine is hydrolysed so that the amino group remains on the protein complex.
n3:packager
n12:271B461D-363D-11E5-9242-09173F13E4C5 n12:271B461B-363D-11E5-9242-09173F13E4C5 n12:271B461C-363D-11E5-9242-09173F13E4C5
n3:synonym
Codecarboxylase Pyridoxal P Pyridoxal-5P Pyridoxal 5'-phosphate Pyridoxal 5-phosphate PLP Pyridoxal-P
n3:synthesisReference
Robert C. Siegel, "Synthesis of cross-links in the helical domain of collagen using pyridoxal 5-phosphate and copper or iron." U.S. Patent US4544638, issued June, 1981.
n25:hasConcept
n26:M0018242
foaf:page
n11:vit_0215.shtml
n3:IUPAC-Name
n9:271B4622-363D-11E5-9242-09173F13E4C5
n3:InChI
n9:271B4628-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n9:271B4627-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n9:271B4624-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n9:271B4625-363D-11E5-9242-09173F13E4C5
n3:SMILES
n9:271B4626-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n9:271B4620-363D-11E5-9242-09173F13E4C5 n9:271B4638-363D-11E5-9242-09173F13E4C5
n3:logP
n9:271B461E-363D-11E5-9242-09173F13E4C5 n9:271B4621-363D-11E5-9242-09173F13E4C5 n9:271B463A-363D-11E5-9242-09173F13E4C5
n3:logS
n9:271B461F-363D-11E5-9242-09173F13E4C5
n13:hasATCCode
n14:A11HA06
n3:H-Bond-Acceptor-Count
n9:271B462E-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n9:271B462F-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n9:271B4629-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n9:271B462A-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n9:271B462C-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n9:271B462B-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n9:271B462D-363D-11E5-9242-09173F13E4C5
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
54-47-7
n3:category
n3:Bioavailability
n9:271B4634-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n9:271B4636-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n9:271B4637-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n9:271B4639-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n9:271B4633-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n9:271B4632-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n9:271B4635-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n9:271B4623-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n9:271B4630-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n9:271B4631-363D-11E5-9242-09173F13E4C5